Clinical trials: Advanced Solid Malignancy
Solid Tumors
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors
This study is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with unresectable, locally advanced, or metastatic solid tumors.
- Trial name
- NCT06001684
- Testing
- IBR854 Cell Injection
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
Advanced Malignancies
A Clinical Study of MIL95 in Advanced Malignancies.
This study is composed of two stages: Part A initial dose escalation and Part B maintenance dose escalation. Both parts will adopt the classical 3+3 dose escalation design.
- Trial name
- NCT04651348
- Testing
- Recombinant Humanized Monoclonal Antibody MIL95
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and…
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT05880043
- Testing
- GIC-102
- Where
- 4 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- GI Cell, Inc.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07435038
- Testing
- BPI-572270
- Where
- 7 sites in Australia, China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumors
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.
- Trial name
- NCT06947226
- Testing
- 9MW2821, Other anti-cancer therapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Cancer, Tumor
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
The purpose of this research study is to determine the highest dose of the drug (BMS-690514) that can be safely given to patients with advanced cancer.
- Trial name
- NCT00329004
- Testing
- BMS-690514
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 89 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid, Malignant Tumors
Phase I Chinese PK
An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.
- Trial name
- NCT00503711
- Testing
- Vandetanib, Vandetanib 300 mg
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Solid Tumors
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
- Trial name
- NCT07596693
- Testing
- KXV01 TCR Lentinvivo Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Cancer, Advanced Solid Malignancies
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies.
- Trial name
- NCT01813474
- Testing
- olaparib
- Where
- 3 sites in Japan
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
NSCLC
Study to Evaluate D-1553 in Subjects With Lung Cancer
This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic…
- Trial name
- NCT05383898
- Testing
- D-1553
- Where
- 2 sites in China
- Volunteers
- 225 people
- Sponsor
- InventisBio Co., Ltd
Small Cell Lung Cancer and Other Solid Tumors
APG-1252 in Patients With SCLC or Advanced Solid Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT03387332
- Testing
- APG-1252
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Tumor
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1032.
- Trial name
- NCT05839106
- Testing
- PM1032 injection
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- Biotheus Inc.
Solid Tumor
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
This was a multicenter, open, multi-cohort extended PHASE I/IIa study, consisting of 2 phases:Phase I (Phase I dose escalation) and Phase II (Phase IIa multi-cohort extension).
- Trial name
- NCT04175847
- Testing
- RC88
- Where
- 4 sites in China
- Volunteers
- 198 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Solid Tumor, Advanced Lymphoma
First in Human, Dose Escalation Study of AN4005
Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors.
- Trial name
- NCT04999384
- Testing
- AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2
- Where
- 7 sites in United States, China
- Volunteers
- 31 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Metastatic Cancer, Solid Tumor
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489343
- Testing
- Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Symphogen A/S
Neoplasms
Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a weekly basis
- Trial name
- NCT00389389
- Testing
- AZD4877
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.